| This report contains COVID-19 specific updates.
Bioinformatics: Technologies and Global Markets
Report Highlights
The global market for bioinformatics should grow from $16.1 billion in 2020 to $24.1 billion by 2025 with a compound annual growth rate (CAGR) of 8.4% for the period of 2020-2025.
Report Includes
- 51 data tables and 84 additional tables
- An overview of the global markets and technologies for bioinformatics
- Analyses of global market trends, with data from 2018, 2019, 2020 and projections of compound annual growth rates (CAGRs) through 2025
- Evaluation of market size and forecast, and market share analysis of bioinformatics based on categories, applications, sequence services and platforms, region, and end-users
- Highlights of technological advancements and innovations in bioinformatics solutions for drug discovery and insights into investments and funding for the development of bioinformatics solutions
- Assessment of challenges and opportunities in the bioinformatics market and description of high-throughput technologies such as next-generation sequencing (NGS), big data analysis and cloud-based solutions
- Coverage of new discoveries in biological sciences; details of antibody-based drug discovery and development; prevalence of chronic diseases and impact analysis of COVID-19 on bioinformatics company
- Identification of innovative companies and technologies that are moving forward in search for elusive pieces of information that will improve diagnoses and treatments of diseases with precision medicines
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Comprehensive company profiles of major players of the industry, including Illumina Inc., Genedata AG, Qlucore AB, GNS Healthcare Inc., Smartgene Services SARL and Real Time Genomics Inc.
Report Scope
The scope of the study encompasses the global bioinformatics market based on geography, category and application. It provides a detailed analysis of recent advances in omic technologies and examines their impact on the bioinformatics market. It discusses the ways in which bioinformatics has been utilized by the pharma and biotech industries to streamline the research and development (R&D) process and improve efficiencies. It provides a detailed analysis of the leading countries, companies and technologies that will drive the field forward.
By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa will be covered in the regional segment. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast value for 2025.
Analyst Credentials
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
Report Highlights
The global bioinformatics market should grow from $7.5 billion in 2018 to $20.0 billion by 2023, with a compound annual growth rate (CAGR) of 21.7% during the period of 2018-2023.
Report Includes
- 31 data tables and 80 additional tables
- Comprehensive details of the global bioinformatics market and relevant technologies
- Analyses of global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Assessment of the market trends and analysis regarding industry service providers and software solution developers, as well as information technology (IT) and bioinformatics service providers that support the pharma and biotech industries
- Review of challenges and opportunities underlying in the bioinformatics market following the adoption of high-throughput technologies such as next-generation sequencing (NGS), the analysis of big data, and the emergence of cloud-based solutions
- Insight into the sequencing and pharmaceutical R&D applications of bioinformatics in drug development and clinical trials, including cheminformatics, next-generation sequencing, metagenomics and data management systems
- A look at the investigational new drug applications, NDA approvals, leading EHRs providers, mobile health technologies, and recent partnerships and agreements in the pharmaceutical and bioinformatic sectors
- Profile description of key pharmaceutical and biotechnology companies, including Dassault Systemes Biovia, Genedata AG, PerkinElmer Informatics Inc., Qlucore AB and Syngene International
Report Highlights
The global market for bioinformatics should grow from $6.4 billion in 2017 to reach $16.0 billion by 2022 at a compound annual growth rate (CAGR) of 20.0% for the period of 2017-2022.
Report Includes
- 28 data tables and 72 additional tables
- An overview of the global market for bioinformatic technologies and their applications
- Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Discussion of the goal of bioinformatics and their role in systems biology
- Insight into the application of bioinformatics on drug development, including cheminformatics, next-generation sequencing, metagenomics and data management systems
- Detailed profiles of major companies in the market, including 3rd Millennium, Inc., Biomatters Ltd., Compugen Ltd., DNASTAR, Inc., and Illumina, Inc.
Report Highlights
The global bioinformatic market was $3.6 billion and $4.1 billion in 2013 and 2014, respectively. This market is expected to reach $8.0 billion in 2019 from $4.7 billion in 2015 at a compound annual growth rate of 14.2% for the period 2014-2019.
Report Includes
- An overview of the global market for bioinformatics based on geography, category and application.
- Analyses of global market trends, with data from 2013 and 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2019.
- Technological descriptions and patenting trends in bioinformatics.
- Analysis of the market's dynamics, including opportunities, drivers, and restraints.
- Examination of the economic environment effecting the deployment of bioinformatics.
- Discussion of other influential factors, such as R&D spending in the pharmaceutical sector, the growth of agrobiotechnology, and the expanded use of microbial genomics.
- Comprehensive company profiles of major players in the industry.
Report Highlights
The global bioinformatics market was valued at nearly $2.8 billion in 2011, nearly $3.2 billion in 2012, and is forecast to grow to nearly $7.5 billion by 2017 after increasing at a compound annual growth rate (CAGR) of 18.7%.
Report Includes
- An overview of the global market for bioinformatics.
- Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Technological descriptions and patenting trends in bioinformatics.
- Examination of the economic environment affecting the deployment of bioinformatics.
- Discussion of other influential factors, such as R&D spending in the pharmaceutical sector, the growth of agrobiotechnology, and the expanded use of microbial genomics.
Report Highlights
-
The worldwide value of bioinformatics is expected to increase from $1.02 billion in 2002 to $3.0 billion in 2010, at an average annual growth rate (AAGR) of 15.8%.
-
The fastest growing market is expected to be analysis software and services. It is estimated to grow from $444.7 million in 2005 to $1.2 billion in 2010.
-
The application of bioinformatics in drug discovery and development is expected to reduce the annual cost of developing a new drug by 33%, and the time for drug discovery by 30%.
-
The pharmaceutical companies are expected to increase their R&D expenditures in the future and a major portion of this spending is expected to go into bioinformatics.